Claudia Schulte

List of Publications by Year
in descending order

90 papers	10,651 citations	81900 39 h-index	45317 90 g-index
95 all docs	95 docs citations	95 times ranked	14052 citing authors

#	Article	IF	Citations
1	Dairy Intake and Parkinson's Disease: A Mendelian Randomization Study. Movement Disorders, 2022, 37, 857-864.	3.9	15
2	Changes in CD163+, CD11b+, and CCR2+ peripheral monocytes relate to Parkinsonâ€™s disease and cognition. Brain, Behavior, and Immunity, 2022, 101, 182-193.	4.1	20
3	GBA-associated PD: chances and obstacles for targeted treatment strategies. Journal of Neural Transmission, 2022, 129, 1219-1233.	2.8	22
4	Mitochondrial and autophagy-lysosomal pathway polygenic risk scores predict Parkinson's disease. Molecular and Cellular Neurosciences, 2022, 121, 103751.	2.2	9
5	The Interaction between <scp>HLAâ€ÐRB1</scp> and Smoking in Parkinson's Disease Revisited. Movement Disorders, 2022, 37, 1929-1937.	3.9	4
6	Soluble <scp>CD163</scp> Changes Indicate Monocyte Association With Cognitive Deficits in Parkinson's Disease. Movement Disorders, 2021, 36, 963-976.	3.9	35
7	Phenylalanine Effects on Brain Function in Adult Phenylketonuria. Neurology, 2021, 96, e399-e411.	1.1	29
8	The Mutation Matters: <scp>CSF</scp> Profiles of <scp>GCase</scp>, Sphingolipids, Î±â€Synuclein in <scp>PD_{GBA}</scp>. Movement Disorders, 2021, 36, 1216-1228.	3.9	40
9	A Novel SNCA A30G Mutation Causes Familial ParkinsonÊ¼s Disease. Movement Disorders, 2021, 36, 1624-1633.	3.9	54
10	Genome sequencing analysis identifies new loci associated with Lewy body dementia and provides insights into its genetic architecture. Nature Genetics, 2021, 53, 294-303.	21.4	198
11	Replication of a Novel Parkinson's Locus in a European Ancestry Population. Movement Disorders, 2021, 36, 1689-1695.	3.9	8
12	Investigation of Autosomal Genetic Sex Differences in Parkinson's Disease. Annals of Neurology, 2021, 90, 35-42.	5.3	29
13	The longevity gene Klotho and its cerebrospinal fluid protein profiles as a modifier for ParkinsonÂ´s disease. European Journal of Neurology, 2021, 28, 1557-1565.	3.3	12
14	Association between CSF alpha-synuclein seeding activity and genetic status in Parkinsonâ€™s disease and dementia with Lewy bodies. Acta Neuropathologica Communications, 2021, 9, 175.	5.2	49
15	Finding genetically-supported drug targets for Parkinsonâ€™s disease using Mendelian randomization of the druggable genome. Nature Communications, 2021, 12, 7342.	12.8	44
16	Selenium speciation analysis in the cerebrospinal fluid of patients with Parkinsonâ€™s disease. Journal of Trace Elements in Medicine and Biology, 2020, 57, 126412.	3.0	23
17	Parkinson's Disease: Glucocerebrosidase 1 Mutation Severity Is Associated with CSF Alphaâ€Synuclein Profiles. Movement Disorders, 2020, 35, 495-499.	3.9	32
18	Genetic modifiers of risk and age at onset in GBA associated Parkinsonâ€™s disease and Lewy body dementia. Brain, 2020, 143, 234-248.	7.6	149

#	Article	IF	Citations
19	Elemental fingerprint: Reassessment of a cerebrospinal fluid biomarker for Parkinson's disease. Neurobiology of Disease, 2020, 134, 104677.	4.4	23
20	Evaluating the Use of Circulating MicroRNA Profiles for Lung Cancer Detection in Symptomatic Patients. JAMA Oncology, 2020, 6, 714.	7.1	84
21	Penetrance of Parkinson's Disease in LRRK2 p.G2019S Carriers Is Modified by a Polygenic Risk Score. Movement Disorders, 2020, 35, 774-780.	3.9	57
22	Intraindividual Neurofilament Dynamics in Serum Mark the Conversion to Sporadic Parkinson's Disease. Movement Disorders, 2020, 35, 1233-1238.	3.9	22
23	A combined miRNAâ€“piRNA signature to detect Alzheimerâ€™s disease. Translational Psychiatry, 2019, 9, 250.	4.8	74
24	Identification of novel risk loci, causal insights, and heritable risk for Parkinson's disease: a meta-analysis of genome-wide association studies. Lancet Neurology, The, 2019, 18, 1091-1102.	10.2	1,414
25	Alterations in Blood Monocyte Functions in Parkinson's Disease. Movement Disorders, 2019, 34, 1711-1721.	3.9	67
26	The endocytic membrane trafficking pathway plays a major role in the risk of Parkinson's disease. Movement Disorders, 2019, 34, 460-468.	3.9	66
27	Dementia with lewy bodies: GBA1 mutations are associated with cerebrospinal fluid alphaâ€synuclein profile. Movement Disorders, 2019, 34, 1069-1073.	3.9	24
28	No association between Parkinson disease and autoantibodies against NMDA-type glutamate receptors. Translational Neurodegeneration, 2019, 8, 11.	8.0	10
29	Parkinson's disease age at onset genomeâ€wide association study: Defining heritability, genetic loci, and Î±â€synuclein mechanisms. Movement Disorders, 2019, 34, 866-875.	3.9	258
30	Machine Learning to Detect Alzheimerâ€™s Disease from Circulating Non-coding RNAs. Genomics, Proteomics and Bioinformatics, 2019, 17, 430-440.	6.9	67
31	Parkinsonâ€™s disease: evolution of cognitive impairment and CSF AÎ²_{1â€“42} profiles in a prospective longitudinal study. Journal of Neurology, Neurosurgery and Psychiatry, 2019, 90, 165-170.	1.9	14
32	Insufficient evidence for pathogenicity of SNCA His50Gln (H50Q) in Parkinson's disease. Neurobiology of Aging, 2018, 64, 159.e5-159.e8.	3.1	30
33	Biallelic Parkin (PARK2) mutations can cause a bvFTD phenotype without clinically relevant parkinsonism. Parkinsonism and Related Disorders, 2018, 55, 145-147.	2.2	6
34	Polygenic load: Earlier disease onset but similar longitudinal progression in Parkinson's disease. Movement Disorders, 2018, 33, 1349-1353.	3.9	10
35	Cholinergic Pathway SNPs and Postural Control in 477 Older Adults. Frontiers in Aging Neuroscience, 2018, 10, 260.	3.4	1
36	No genetic association between attention-deficit/hyperactivity disorder (ADHD) and Parkinsonâ€™s disease in nine ADHD candidate SNPs. ADHD Attention Deficit and Hyperactivity Disorders, 2017, 9, 121-127.	1.7	13

#	Article	IF	Citations
37	Cognitive impairment in Glucocerebrosidase (GBA)â€associated PD: Not primarily associated with cerebrospinal fluid Abeta and Tau profiles. Movement Disorders, 2017, 32, 1780-1783.	3.9	19
38	Metformin reverses TRAP1 mutation-associated alterations in mitochondrial function in Parkinsonâ€™s disease. Brain, 2017, 140, 2444-2459.	7.6	76
39	SNPs in AÎ² clearance proteins. Neurology, 2017, 89, 2335-2340.	1.1	13
40	Inflammatory profile in LRRK2-associated prodromal and clinical PD. Journal of Neuroinflammation, 2016, 13, 122.	7.2	57
41	<scp>A</scp>lphaâ€synuclein gene variants may predict neurostimulation outcome. Movement Disorders, 2016, 31, 601-603.	3.9	15
42	A genome-wide association study in multiple system atrophy. Neurology, 2016, 87, 1591-1598.	1.1	139
43	Prospective longitudinal course of cognition in older subjects with mild parkinsonian signs. Alzheimer's Research and Therapy, 2016, 8, 42.	6.2	14
44	Deletions at 22q11.2 in idiopathic Parkinson's disease: a combined analysis of genome-wide association data. Lancet Neurology, The, 2016, 15, 585-596.	10.2	77
45	GBAâ€associated Parkinson's disease: Reduced survival and more rapid progression in a prospective longitudinal study. Movement Disorders, 2015, 30, 407-411.	3.9	214
46	NeuroX, a fast and efficient genotyping platform for investigation of neurodegenerative diseases. Neurobiology of Aging, 2015, 36, 1605.e7-1605.e12.	3.1	96
47	Neurodegenerative CSF markers in genetic and sporadic PD: Classification and prediction in a longitudinal study. Parkinsonism and Related Disorders, 2015, 21, 1427-1434.	2.2	20
48	Comparable Autoantibody Serum Levels against Amyloid- and Inflammation-Associated Proteins in Parkinsonâ€™s Disease Patients and Controls. PLoS ONE, 2014, 9, e88604.	2.5	36
49	Large-scale meta-analysis of genome-wide association data identifies six new risk loci for Parkinson's disease. Nature Genetics, 2014, 46, 989-993.	21.4	1,685
50	Analysis of Genome-Wide Association Studies of Alzheimer Disease and of Parkinson Disease to Determine If These 2 Diseases Share a Common Genetic Risk. JAMA Neurology, 2013, 70, 1268-76.	9.0	51
51	SNCA: Major genetic modifier of age at onset of Parkinson's disease. Movement Disorders, 2013, 28, 1217-1221.	3.9	36
52	A pathway-based analysis provides additional support for an immune-related genetic susceptibility to Parkinson's disease. Human Molecular Genetics, 2013, 22, 1039-1049.	2.9	122
53	No association between polymorphisms in the glutamate transporter SLC1A2 and Parkinson's disease. Movement Disorders, 2013, 28, 1305-1306.	3.9	5
54	Using genome-wide complex trait analysis to quantify 'missing heritability' in Parkinson's disease. Human Molecular Genetics, 2012, 21, 4996-5009.	2.9	176

#	Article	IF	Citations
55	S100B is increased in Parkinsonâ€™s disease and ablation protects against MPTP-induced toxicity through the RAGE and TNF-Î± pathway. Brain, 2012, 135, 3336-3347.	7.6	159
56	Use of support vector machines for disease risk prediction in genome-wide association studies: Concerns and opportunities. Human Mutation, 2012, 33, 1708-1718.	2.5	42
57	Long-term follow-up of subthalamic nucleus stimulation in glucocerebrosidase-associated Parkinsonâ€™s disease. Journal of Neurology, 2012, 259, 1970-1972.	3.6	24
58	POLG and PEO1 (Twinkle) mutations are infrequent in PSP-like atypical parkinsonism: a preliminary screening study. Journal of Neurology, 2012, 259, 2232-2233.	3.6	0
59	Analysis of TGFB1 in European and Japanese Moyamoya disease patients. European Journal of Medical Genetics, 2012, 55, 531-534.	1.3	16
60	NIPA1 polyalanine repeat expansions are associated with amyotrophic lateral sclerosis. Human Molecular Genetics, 2012, 21, 2497-2502.	2.9	49
61	GBA -associated PD. Neurology, 2012, 79, 213-220.	1.1	40
62	Cooperative Genome-Wide Analysis Shows Increased Homozygosity in Early Onset Parkinson's Disease. PLoS ONE, 2012, 7, e28787.	2.5	21
63	Serum and Cerebrospinal Fluid Levels of Transthyretin in Lewy Body Disorders with and without Dementia. PLoS ONE, 2012, 7, e48042.	2.5	23
64	Genetic basis of Parkinson's disease: inheritance, penetrance, and expression. The Application of Clinical Genetics, 2011, 4, 67.	3.0	96
65	Serum and Cerebrospinal Fluid Uric Acid Levels in Lewy Body Disorders: Associations with Disease Occurrence and Amyloid-Î² Pathway. Journal of Alzheimer's Disease, 2011, 27, 119-126.	2.6	40
66	Analysis of ACTA2 in European Moyamoya disease patients. European Journal of Paediatric Neurology, 2011, 15, 117-122.	1.6	38
67	Imputation of sequence variants for identification of genetic risks for Parkinson's disease: a meta-analysis of genome-wide association studies. Lancet, The, 2011, 377, 641-649.	13.7	845
68	Common genetic polymorphisms in Moyamoya and atherosclerotic disease in Europeans. Child's Nervous System, 2011, 27, 245-252.	1.1	24
69	Clinical and brain imaging characteristics in leucineâ€rich repeat kinase 2â€“associated PD and asymptomatic mutation carriers. Movement Disorders, 2011, 26, 2335-2342.	3.9	65
70	Angiogenin variants in Parkinson disease and amyotrophic lateral sclerosis. Annals of Neurology, 2011, 70, 964-973.	5.3	168
71	Polymorphisms in TGFB1 and PDGFRB are associated with Moyamoya disease in European patients. Acta Neurochirurgica, 2010, 152, 2153-2160.	1.7	46
72	POLG, but not PEO1, is a frequent cause of cerebellar ataxia in Central Europe. Movement Disorders, 2010, 25, 2678-2682.	3.9	31

#	Article	IF	Citations
73	Complex hyperkinetic movement disorders associated with POLG mutations. Movement Disorders, 2010, 25, 2472-2475.	3.9	14
74	ARHGEF7 (BETA-PIX) Acts as Guanine Nucleotide Exchange Factor for Leucine-Rich Repeat Kinase 2. PLoS ONE, 2010, 5, e13762.	2.5	55
75	A large genome scan for rare CNVs in amyotrophic lateral sclerosis. Human Molecular Genetics, 2010, 19, 4091-4099.	2.9	51
76	Dissecting the role of the mitochondrial chaperone mortalin in Parkinson's disease: functional impact of disease-related variants on mitochondrial homeostasis. Human Molecular Genetics, 2010, 19, 4437-4452.	2.9	121
77	Neprilysin Activity in Cerebrospinal Fluid is Associated with Dementia and Amyloid-Î²42 Levels in Lewy Body Disease. Journal of Alzheimer's Disease, 2010, 22, 933-938.	2.6	23
78	The CST3 BB Genotype and Low Cystatin C Cerebrospinal Fluid Levels are Associated with Dementia in Lewy Body Disease. Journal of Alzheimer's Disease, 2010, 19, 937-942.	2.6	32
79	ATAXIA WITH OPHTHALMOPLEGIA OR SENSORY NEUROPATHY IS FREQUENTLY CAUSED BY POLG MUTATIONS. Neurology, 2009, 73, 898-900.	1.1	69
80	Cortical PIB binding in Lewy body disease is associated with Alzheimer-like characteristics. Neurobiology of Disease, 2009, 34, 107-112.	4.4	177
81	No differences of butyrylcholinesterase protein activity and allele frequency in Lewy body diseases. Neurobiology of Disease, 2009, 35, 296-301.	4.4	15
82	SNCA variants are associated with increased risk for multiple system atrophy. Annals of Neurology, 2009, 65, 610-614.	5.3	257
83	Singleâ€cell expression profiling of dopaminergic neurons combined with association analysis identifies pyridoxal kinase as Parkinson's disease gene. Annals of Neurology, 2009, 66, 792-798.	5.3	49
84	Effect of genetic variation in Kv1.3 on olfactory function. Diabetes/Metabolism Research and Reviews, 2009, 25, 523-527.	4.0	27
85	A single-nucleotide polymorphism of the osteopontin gene may contribute to a susceptibility to Lewy body disease. Journal of Neural Transmission, 2009, 116, 599-605.	2.8	16
86	Genome-wide association study reveals genetic risk underlying Parkinson's disease. Nature Genetics, 2009, 41, 1308-1312.	21.4	1,745
87	The transcription factor PITX3 is associated with sporadic Parkinson's disease. Neurobiology of Aging, 2009, 30, 731-738.	3.1	108
88	Further delineation of the association signal on chromosome 5 from the first whole genome association study in Parkinson's disease. Neurobiology of Aging, 2009, 30, 1706-1709.	3.1	1
89	PARK11 gene (GIGYF2) variants Asn56Ser and Asn457Thr are not pathogenic for Parkinson's disease. Parkinsonism and Related Disorders, 2009, 15, 532-534.	2.2	28
90	Type and frequency of mutations in the LRRK2 gene in familial and sporadic Parkinson's disease*. Brain, 2005, 128, 3000-3011.	7.6	247